Patients with high MXD3 expression had poorer survival than patients with low MXD3 expression in PAAD (Figure 6A; p = 0.004), BLCA (Figure 6B; p = 0.038), LUAD (Figure 6C; p < 0.0001), ESCA (Figure 6D; p = 0.024), SKCM (Figure 6E; p = 0.034), and GBM (Figure 6F; all p = 0.042). This evidence concerns the gene MXD3 and pancreatic adenocarcinoma.